This project will investigate using entirely animal free components to screen a range of biological inks for their potential to improve the mechanical structure of printed skin for skin disease models.

Artemijs will use animal free products to re-establish the human heart-in-a-dish and compare an animal free system and recapitulate key experiments for comparison with existing model data sets.

Fengjiao will explore the effect of animal free simulated lung fluid on environmental nano and microparticles in order to develop better human relevant models for lung toxicology.

Heidi will develop technology of building neural circuits with defined architecture for better understanding of neurodevelopmental diseases such as epilepsy.

Lucille will establish a new method of differentiating neuron-like cells into mature excitatory neurons without using any animal-derived materials.

Michael will use the available clinical data from existing breast cancer patients to investigate how different types of the disease contribute to disease severity and patient outcome.

Patricia will validate a human cell-based model to study monitor cellular stress and their effect on some characteristics of dementia.

Pawel will test the grouping approach to predict multi-component nanomaterials toxicity to reduce need for animal testing for these new materials.

Rebecca will generate a single-stranded DNA aptamer to detect a specific human protein receptor called the formyl peptide receptor to replace animal-derived antibodies.

Rita will develop an hydrogel scaffold that can be implanted into the body and release drugs under determined mechanical stimulation for new drug delivery systems.

Ryan will use modern sequencing technology to assess the gene expression of cultured lung blood vessel cells which have been donated from idiopathic pulmonary fibrosis patients to help inform the creation of new treatments.

Seyta will assess the feasibility of using the membrane derived from fruit such as lychee and citrus, as a possible scaffold material.

Sophie will develop a human tissue derived laboratory model to study drug interactions within a cancerous environment.

Toba will make existing ImmuPHAGE models fully human relevant to be applied in wide range of respiratory toxicity studies.

Tom will develop an effective 3D model using human cells which can be tailored to mimic the bone of an osteoporosis sufferer.

William will take a closer look at how psychoactive substances act in certain receptors in the brain to contribute to the development of animal free chemical sensing platforms.